Mandy Ching

Cooley advised Bicycle Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of medicines referred to as Bicycle molecules, on its $555.5 million private placement offering. Partners Laura Berezin, Jaime Chase and Claire Keast-Butler led the Cooley team.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.